- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01251484
BIBF 1120 in Recurrent Glioblastoma Multiforme
Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme
VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases. BEV may stop the growth of tumor cells by blocking blood flow to the tumor. Cediranib, a pan-VEGF inhibitor has shown promising results in recurrent GBM.
VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to BIBF-1120 in such circumstances may open a new treatment option in GBM. In additional, recurrent glioblastomas have an extremely poor prognosis, so innovative therapies are needed.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Written informed consent
Histological verification of primary GBM and failure after radiotherapy and TMZ
- Previously received radiotherapy and TMZ
More than 4 weeks since any of the following prior treatments
- Chemotherapy (6 weeks for nitrosureas or mitomycin C)
- Radiotherapy to nontarget lesions or lesions that are not to be biopsied
- Investigational agents
- More than 6 months since prior major surgery or open biopsy and recovered (only 6 weeks required if operation is for recurrent BGM)
- ● ECOG performance status 0-1
- Age > 18 years
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- Fertile females must use anticonception (p- pills, IUD, depot injection of gestagen, subdermal
- implantation, hormonal vaginal ring or transdermal depot plaster, throughout the study and 3
- months after discontinuation of study drugs. Fertile men must use dobbelt barrier method
- (preservative with sperm inhibiting creme) or female partner uses the above mentioned
- contraception.
- Fertile males must use preservatives.
Exclusions criteria
- Prior treatment with BIBF 1120 or any other VEGFR inhibitor, except bevacizumab in Group 2
- Chemo-, hormono-, radio-(except for brain and extremities) or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug.
- Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy
- Treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trial
- Therapeutic anticoagulation( except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid<325mg per day
- Major injuries within the past 10 days prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period
- History of clinically significant haemorrhagic or thromboembolic event in the past 6 months
- Known inherited predisposition to bleeding or thrombosis
- Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure > NYHA II, serious cardiac arrhythmia, pericardial effusion)
- Proteinuria CTCAE grade 2 or greater
- Hepatic function: total bilirubin outside of normal limits; ALT or AST > 1.5 ULN
Coagulation parameters: International normalised ratio ( INR) > 2, prothrombin time
- (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional ULN
- Absolute neutrophil count ( ANC) < 1500/ml, platelets < 100000/ml, Haemoglobin < 9.0 g/dl
- Other malignancies within the past 5 years other then basal cell skin cancer or carcinoma in situ of the cervix
- Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
- Active or chronic hepatitis C and/or B infection
- Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
- Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.
- Pregnancy or breast feeding
- Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
- active alcohol or drug abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate
Time Frame: Response evaluation every 8 weeks
|
MacDonald criteria
|
Response evaluation every 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Assessed every 2 weeks
|
CTCAE version 4.0
|
Assessed every 2 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Recurrence
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Nintedanib
Other Study ID Numbers
- BIBF1120 GBM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioblastoma
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...WithdrawnRecurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated GlioblastomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
-
University of OklahomaGlaxoSmithKlineTerminatedRecurrent Glioblastoma | Recurrent Glioma | Recurrent Astrocytoma | Recurrent OligodendrogliomaUnited States
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; Lantheus Medical Imaging; CarTheraRecruitingGlioblastoma | Glioblastoma Multiforme | Gliosarcoma | GBM | Recurrent Glioblastoma | Glioblastoma, IDH-wildtypeUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IVUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
Clinical Trials on BIBF1120
-
Boehringer IngelheimCompleted
-
AHS Cancer Control AlbertaBoehringer Ingelheim; Cross Cancer InstituteWithdrawnSmall Cell Lung Cancer | Platinum-sensitiveCanada
-
Samsung Medical CenterUnknownRecurrent or Metastatic Salivary Gland Cancer of the Head and NeckKorea, Republic of
-
National Taiwan University HospitalUnknownUrothelial CarcinomaTaiwan
-
University Hospital MuensterBoehringer IngelheimUnknownAcute Myeloid LeukemiaGermany
-
European Organisation for Research and Treatment...CompletedDifferentiated Thyroid Cancer (DTC) | Medullary Thyroid Cancer (MTC)France, Belgium, Denmark, Italy, Netherlands, Germany, Poland, Spain, United Kingdom
-
European Organisation for Research and Treatment...Boehringer IngelheimTerminatedSarcoma, Soft TissueFrance, Belgium, Poland, Spain, Lithuania, Netherlands, United Kingdom
-
University of Alabama at BirminghamBoehringer IngelheimCompletedRenal Cell Carcinoma | Non-squamous Non-small Cell Lung Cancer | Cervical Carcinoma | Colorectal Adenocarcinoma | Platinum-refractory Ovarian CarcinomaUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingNon Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Lung Cancer, Nonsmall CellUnited States
-
Boehringer IngelheimCompletedPulmonary FibrosisArgentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more